Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Approved for marketing × INDUSTRY × lazertinib × Clear all

Status

Active not recruiting 5 Recruiting 4 Completed 1 Approved for marketing 1

Sponsor Class

Study Type

Expanded_access 1

Sponsor

Cancer Type

Conditions

Lung Neoplasms 1

Interventions

Afatinib 3 niraparib 2 lenvatinib 2 ibrutinib 2 abemaciclib 2 Trastuzumab 2 Gefitinib 2 Capecitabine 2 Abiraterone Acetate 2 3-Iodobenzylguanidine 2 zenocutuzumab 1 vorasidenib 1 tucatinib 1 trilaciclib 1 tovorafenib 1 talquetamab 1 tafasitamab 1 selpercatinib 1 sacituzumab govitecan 1 ripretinib 1 ponatinib 1 pomalidomide 1 pirtobrutinib 1 pertuzumab 1 olaratumab 1 olaparib 1 nilotinib 1 mobocertinib 1 margetuximab 1 lutetium Lu 177 dotatate 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04829422 2022-03-03

Early Access Program of Lazertinib in Republic of Korea

Yuhan Corporation

Approved for marketing

Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡